Calypte Only Company with Full Menu of Tests.

By RODRIQUE NGOWI
Associated Press Writer

http://hosted.ap.org/dynamic/stories/A/...T&CTIME=2005-07-23-20-29-18  
 
NAIROBI, Kenya (AP) -- Former President Bill Clinton launched a program Saturday that will nearly double the number of children receiving treatment for HIV infection in Kenya by the end of the year.

Some 100,000 children are infected with HIV, but only 1,200 receive treatment. The Clinton Foundation's Pediatric HIV/AIDS Initiative will provide treatment to an additional 1,000 children in this East African nation.

Clinton flew to Rwanda later Saturday and donated a year's supply of anti-retroviral treatment for 2,500 children infected with HIV, the virus that causes AIDS.

The initiative is part of the foundation's goal to get 10,000 children on anti-retroviral treatment in at least 10 countries by the end of 2005.

 
 
Clinton has raised funds from private donors led by the Children Investment Fund Foundation, a London-based charity that funds projects to improve the lives of children in poor countries. The U.S.-based investment fund Lone Pine Capital has also made a substantial contribution.

Children account for one-sixth of annual HIV/AIDS deaths worldwide, but represent less than 5 percent of current treatment coverage, according to the U.N.'s World Health Organization.

The lack of coverage is a result of difficulties associated with pediatric HIV/AIDS care. Diagnosis of the infection in children under 18 months old has been expensive and complex, according to a statement from the Clinton Foundation.

Few pediatricians in developing countries have anti-retroviral experience. The cost of pediatric medications has also been prohibitive, four to five times that of most affordable adult formulations, partly because suppliers have not received large orders.

 
Clinton's visit to Rwanda was intended to highlight the progress made in extending HIV/AIDS treatment across the small central African nation.

In the past year alone, Rwanda has tripled the number of people on anti-retroviral treatment to approximately 13,250 - about 20 percent of those who need it - and increased the number of treatment sites from 20 to 57, according to the foundation.

The foundation has worked with Rwanda's government since 2002 to help develop and extend the availability of HIV/AIDS treatment.

Rwanda is the final stop on Clinton's six-nation tour of Africa, aimed at focusing attention on the continent's AIDS crisis.

The Clinton Foundation HIV/AIDS Initiative has partnerships with more than a dozen countries in Africa, the Caribbean and Asia.

---

Associated Press writer Edward Rwema contributed to this report from Kigali, Rwanda.

© 2005 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed. Learn more about our Privacy Policy.

Gruß

C.O  

Joelu ist für immer gesperrt...




Gruß

C.O  

Ihr seit wilkommen



Gruß

C.O  

mal sehen was uns diese woche bechert *g*  

 

unverändert 0,20 bei 0 Umsatz an ?!?!  

volumen ca 450k, also fast nix  

e May Be Removed From Listing on the American Stock Exchange if We Fail to Meet
Continuing Listing Standards.

On June 22, 2005,  we received a letter from the American  Stock  Exchange  (the
"Amex")  notifying us that we are not in  compliance  with certain of the Amex's
continued listing standards. Specifically, the Amex noted that the we are not in
compliance with the standards because we (i) have  stockholders'  equity of less
than $2,000,000 and losses from continuing  operations  and/or net losses in two
out of our three most recent fiscal  years;  (ii) have  stockholders'  equity of
less than $4,000,000 and losses from continuing  operations and/or net losses in
three out of our four most recent  fiscal  years;  and (iii) have  stockholders'
equity of less than $6,000,000 and losses from continuing  operations and/or net
losses in our five most recent fiscal years.

To maintain the listing of our common  stock on the Amex,  we must submit a plan
by July 22, 2005,  advising the Amex of the actions we have taken, or will take,
to bring the Company into compliance with the continued listing standards within
a maximum of 18 months of receipt of the notification letter. Although we may be
able to continue our listing  during the 18 month period,  we will be subject to
periodic reviews to determine whether we are making progress consistent with the
plan. If we do not make progress consistent with the plan during the plan period
or if we are not in  compliance  with the  continued  listing  standards  at the
conclusion of the plan period,  the Amex may initiate  delisting  proceedings as
appropriate.  If we submit a plan that is not  accepted  by the Amex,  we may be
subject to earlier delisting  proceedings.  We are currently  analyzing specific
actions which we may take in response to the Amex's  notification  letter and we
intend  to  submit a plan to the  Amex.  Although  we  believe  our plan will be
acceptable and meet the Amex guidelines for continued  listing,  there can be no
assurance  that Amex will accept our plan or that we will achieve the objectives
required to comply with the continued listing standards.

The public  trading of our common stock and the ability of our  stockholders  to
sell  their  shares  could  be  significantly  impaired  if we fail to meet  the
continued  listing  standards and are removed from the Amex.  In that case,  our
common  stock  would  trade  either on the OTC  Bulletin  board,  on a  regional
exchange,  or in the pink sheets,  which could have a detrimental  impact on our
trading volume and/or share value.


Our Issuance of Warrants,  Options and Stock Grants to Consultants  for Services
and the  Granting of  Registration  Rights for the  Underlying  Shares of Common
Stock May Have a Negative Effect on the Trading Price of Our Common Stock.

As we  continue  to look for ways to  minimize  our use of cash while  obtaining
required  services,  we expect to continue to issue  warrants  and options at or
below the current  market price or make  additional  stock bonus grants.  During
2004,  we issued  approximately  2.1 million  shares in payment  for  consulting
services and for the acquisition of intellectual property and equipment.  During
the first  quarter  of 2005,  we issued  approximately  0.1  million  shares and
approximately  1.2 million options at market in payment of consulting  services.
In addition to the potential dilutive effect of issuing a large number of shares
or options, there is the potential that a large number of the shares may be sold
on the open market at any given time,  which  could  place  additional  downward
pressure on the trading price of our common stock.

                                      5



The Price of Our Common Stock Has Been Highly  Volatile  Due to Several  Factors
Which Will Continue to Affect the Price of Our Stock.

Our common  stock has traded as low as $0.18 per share and as high as $0.745 per
share in the twelve  months  ended March 31,  2005.  We believe that some of the
factors leading to the volatility include:

o     price and volume  fluctuations  in the stock  market at large which do not
     relate to our operating performance;

o     fluctuations in our operating results;

o     concerns about our ability to finance our continuing operations;

o     financing  arrangements  which may require the  issuance of a  significant
     number  of  shares  in  relation   to  the  number  of  shares   currently
     outstanding, including anti-dilution provisions;

o     announcements of technological innovations or new products which we or our
     competitors make;

o     FDA, SEC and international regulatory actions;

o     availability of reimbursement  for use of our products from private health
     insurers,   governmental  health  administration   authorities  and  other
     third-party payors;

o     developments with respect to patents or proprietary rights;

o     public concern as to the safety of products that we or others develop;

o     changes in health care policy in the United States or abroad;

o     changes in stock market analysts' recommendations regarding Calypte, other
     medical products companies or the medical product industry generally;

o     fluctuations in market demand for and supply of our products;

o     certain world conditions,  such as an economic downturn, natural disasters
     or terrorist attacks; and

o     anti-American  sentiment in certain  international markets where we market
     or anticipate marketing our products.


We Are  Subject to  Governmental  and Stock  Exchange  Regulations  That  Impose
Operational and Reporting Requirements.

The  Sarbanes-Oxley  Act of 2002 and our listing on the American  Stock Exchange
(Amex) in August 2004 required us to modify or supplement  some of our corporate
governance and securities  disclosure and compliance  practices.  The Securities
and Exchange Commission and the Amex have revised, and continue to revise, their
regulations and policies. These developments have increased, and are expected to
increase, our legal, compliance and financial reporting costs. Failure to comply
with present or future laws,  rules and  regulations of any kind that govern our
business  could  result in  suspension  or  cessation of all or a portion of our
operations, or the imposition of significant  administrative,  civil or criminal
penalties, any of which could harm our business.


Failure to Achieve and Maintain Internal Controls in Accordance With Section 404
of the  Sarbanes-Oxley  Act of 2002 Could Have A Material  Adverse Effect on Our
Business and Stock Price.

We  are in  the  process  of  examining  and  evaluating  our  internal  control
procedures to satisfy the requirements of Section 404 of the Sarbanes-Oxley Act,
which will require our management to annually  assess the  effectiveness  of our
internal controls over financial reporting and our independent registered public
accounting firm to report on our assessment  beginning with our Annual Report on
Form 10-KSB for the year ending  December 31, 2006.  While we expect to complete
our  documentation,  testing and  remediation of any identified  deficiencies in
time to meet the deadline for compliance  with the  requirements of Section 404,
there  can be no  assurance  that  we  will do so.  In  addition,  if we fail to
maintain the adequacy of our internal controls or fail to implement required new
or improved  controls,  as such control standards are modified,  supplemented or
amended from time to time,  we may not be able to ensure that we can conclude on
an  ongoing  basis  that we have  effective  internal  controls  over  financial
reporting  in  accordance  with  Section 404.  Effective  internal  controls are
necessary for us to produce reliable  financial reports and are important in the
prevention of financial fraud. If we cannot produce reliable  financial  reports
or prevent fraud, our business and operating results could be harmed,  investors
could lose confidence in our reported financial information,  and there could be
a material adverse effect on our stock price.


Gruß

C.O  

denke nicht dass dies einen grossen einfluss auf den kurs haben wird....  

...on April 18, 2005,  we entered into a non-binding
letter  of  intent  to sell  the  Legacy  Business  to  Maxim  Biomedical,  Inc.
("Maxim").  Effective May 1, 2005, we entered into a manufacturing  services and
management  agreement (the  "Agreement") with Maxim pursuant to which Maxim will
manufacture,  ship and perform quality  control  procedures for us in connection
with the Legacy Business. Under the terms of the Agreement, Maxim has hired some
of our ex-employees  and we have transferred our current  inventory to Maxim for
its use under the Agreement. Pursuant to the Agreement, Maxim has the right, but
not the obligation, to purchase the assets of the Legacy Business on terms to be
negotiated between the parties. We will remain liable for our Rockville facility
and  equipment  lease  obligations,  however,  we expect to reduce our operating
expenses through this arrangement.




During the third quarter of 2005,  we expect to complete  either the sale of the
Legacy  Business  to  Maxim  or  the  closure  of  the  Rockville  facility  and
termination  of Legacy  Business  operations  as well as the  transition  of our
corporate  headquarters  from  California to the Portland,  Oregon area. We have
incurred severance costs for certain personnel  terminated at Rockville and will
incur severance costs for certain administrative  personnel not transitioning to
Oregon.   We  expect   that  our   restructuring   activities   will  result  in
severance-related  charges of up to approximately $500,000 in the second quarter
of 2005. We have also incurred  approximately  $1 million in second quarter 2005
expenses from the transfer of our inventory to Maxim under the Agreement. We may
also be liable for lease costs for the California  offices  through July 2007 in
the event we are unable to sublease that facility.

Upon successful  completion of a sale of the Legacy Business, we believe that we
will have significantly reduced our monthly operating burn rate as compared with
historical levels. If we are unable to complete such a transaction, we may incur
costs to decommission the Rockville  facilities;  on-going facility lease costs,
until and unless  sub-lease  opportunities  are available and on-going  lease or
lease termination  costs associated with leased  equipment.  We cannot currently
estimate  those costs,  but they will  increase our cash burn rate in comparison
with the sale  alternative.  Under either scenario,  the revenue stream from our
Legacy Business  products will have been eliminated and we will rely on revenues
from the sale of our BED Incidence  Test and,  following  regulatory  approvals,
from the sale of our HIV-1/2 Rapid Tests internationally.

We believe that the geographic  consolidation of our domestic operations and the
termination  of our  Legacy  Business  resulting  from this  restructuring  will
improve  our  operational  efficiency,  decrease  our cash burn and permit us to
concentrate on expediting the procedures  necessary to commercialize the HIV-1/2
Rapid  Tests and  thereby  begin the  process of  building  the  revenue  stream
necessary  to support our  operations  and achieve our  financial  objective  of
sustained profitable operations and increased stockholder value.
 

Calypte Biomedical Files American Stock Exchange Plan
PLEASANTON, Calif., July 26 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (Amex: HIV) announced today that it has timely filed with the American Stock Exchange (the "Amex") a plan of action that the Company believes will bring it into compliance with the continued listing standards of the Amex. On June 22, 2005, the Company received a letter from the Amex notifying the Company that it is not in compliance with certain of the Amex's continued listing standards set forth in the Amex's Company Guide and indicating that the Company has a period of 18 months in which to execute a plan to regain compliance.

   In accordance with Rule 1009 of the Amex Company Guide, the

    "Exchange staff will evaluate the Plan, including any additional
    documentation that supports the Plan, and make a determination as to
    whether the company has made reasonable demonstration in the Plan of an
    ability to regain compliance with the continued listing standards within
    45 days of receipt of the proposed Plan [on July 22, 2005] and will
    promptly notify the company of its determination in writing."

While the Company believes that the milestones, financial projections and strategic initiatives outlined in the plan make a reasonable demonstration of its ability to regain compliance with the continued listing standards within the 18-month timeframe specified by the Amex, it can offer no assurances that the Amex will accept the plan.

About Calypte Biomedical:

Calypte Biomedical Corporation is a US-based healthcare company focused on the development and commercialization of diagnostic testing products for the detection of sexually transmitted diseases. Calypte specializes in novel tests such as the HIV-1 BED Incidence EIA and is engaged in developing and commercializing new diagnostic test products for the rapid detection of HIV and other sexually transmitted diseases, several of which do not require blood samples. Calypte believes that there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in lesser-developed countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB/A (No. 2) for the year ended December 31, 2004 and its subsequent filings with the SEC.

SOURCE  Calypte Biomedical Corporation
   -0-                             07/26/2005
   /CONTACT:  Richard Brounstein, EVP and CFO, Calypte Biomedical
Corporation, +1-925-730-7200, rbrounstein@calypte.com; or Tim Clemensen,
Rubenstein Investor Relations, +1-212-843-9337, tclemensen@rubensteinir.com /
   

Gruß

C.O  

 

 

 

Joelu ,

du wirst nie begreifen.

Dein Beitrag macht mir wie so oft keinen gesunden eindruck..

Pass auf dich auf und bis nimmer wieder sehen...


Gruß

C.O  

 

er kann es nicht lassen...  

 

Wann sieht broker endlich ein, dass Calypte joelu 20.07.05 19:12



im August eher bei 0,15$ steht als bei seinen 5$?

Stattdessen setzt er mich in seinem Thrad auf "ignore", was ihm aber nicht helfen wird, die Wahrheit nicht sehen zu müssen?

Broker: eine kostenlose Bollerwagenfahrt durch Deine Stadt...mit Dir vorne als Zugpferd...
 

so ne hassliebe zu caly ist schon hart *g*
ist aber lustig dass du meinst ich hätte bei den moderatoren was im brett...
ist echt nicht so baby!!  

sowie so blind jede aussage.

ich wollte nur mal zeigen, was hier passiert, wenn willkür an der tagesordnung ist und sich jeder mit hilfe oder hilfe der mods über alle grenzen hinwegsetzt.

ich werde uch dann und wann ein paar neue oder alten fakten zu caly liefern, so wie ich gerade bock habe. normalerweise hätte ich gesagt, ich lasse es.

so aber spiele ich euer spielchen einfach mal mit..."nicht war"? alter
"legasteniker"....*ggggg*, um es mit deinen worten zu sagen...  

tja , so ist es Joelu alias giants alias ...... wie oft willst du es versuchen??

Ich hatte zu seiner Zeit dir etwas vorgeschlagen gehabt, weiß du noch??

Fachmännische Hilfe ......


Gruß

C.O  

hat es nur euch. schau mal auf den kurs. aber klar, schlage ich dir fachmännische hilfe vor, werde ich dafür direkt für 2 tage gesperrt. bei dir laufen die dinge so durch...nun gut. es lebe die willkür.

caly auf 0,17?


Time & Sales most recent  next page
Rec. Time Action Price Volume
1:42:12 PM Ask 0.18  55400  
1:42:06 PM Ask 0.18  11400  
1:41:52 PM Trade 0.17  9000  
1:41:52 PM Trade 0.17  5000  
1:41:52 PM Trade 0.17  5000  
1:41:52 PM Trade 0.17  10000  
1:41:52 PM Trade 0.17  5000  
1:41:52 PM Trade 0.17  10000  
1:41:52 PM Trade 0.17  100  
1:41:52 PM Trade 0.17  100  
1:41:52 PM Trade 0.17  100  
1:41:52 PM Trade 0.17  100  
1:41:52 PM Trade 0.17  100  
1:41:52 PM Trade 0.17  100  
1:41:52 PM Trade 0.17  100  
1:41:52 PM Trade 0.17  100  
1:41:52 PM Trade 0.17  100  
1:41:52 PM Trade 0.17  100  
1:41:52 PM Trade 0.17  100  
1:41:52 PM Trade 0.17  100  
1:41:52 PM Trade 0.17  100  
1:41:52 PM Trade 0.17  100  
1:41:52 PM Trade 0.17  100  


wann kommt der $, damit du endlich verkaufen kannst?

an der OTC kommt er eher, da wird mehr gezockt...  

versuch deine Maschen wo anders umzusetzen. RB fällst du nicht auf, da dich ja jeder kennt.

Unsere Mods leisten eine hervoragende Arbeit, da kann man Stolz sein ...


Gruß

C.O